This Phase 1 study is designed to determine the photoallergic potential of PEP005 Gel, 0.01% and it's vehicle on normal skin.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
50
PEP005 (ingenol mebutate) Gel, 0.01%
TKL Research, Inc.
Paramus, New Jersey, United States
To determine the photoallergic (sensitizing) potential of PEP005 Gel and it's vehicle on normal skin.
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.